Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment

Table 4 Predictive factors for 2-year disease-free survival rate and grade III or IV toxicity in patients with gastric cancer who underwent adjuvant TS-1 treatment

Variables		2-year disease-free survival rate	P	Grade III or IV toxicity n (%)	P
Gender	Male (n = 24)	75%	0.68	6 (25.0)	0.33
Gender	Female (n = 16)	74%	0.68	2 (12.5)	0.33
Age	≥65 (n = 13)	82%	0.29	1 (7.7)	0.18
Age	<65 (n = 27)	50%	0.29	7 (25.9)	0.18
Histological type	Diffuse type (n = 25)	74%	0.57	6 (24.0)	0.41
Histological type	Intestinal type (n = 15)	75%	0.57	2 (13.3)	0.41
ECOG performance status scale	0 (n = 32)	74%	0.63	6 (18.8)	0.74
ECOG performance status scale	1 to 2 (n = 8)	75%	0.63	2 (25.0)	0.74
Type of gastrectomy	Total (n = 15)	72%	0.66	6 (40.0)	0.014
Type of gastrectomy	Subtotal (n = 25)	76%	0.66	2 (8.0)	0.014
T stage	1 to 2 (n = 28)	82%	0.44	6 (21.4)	0.73
T stage	3 to 4 (n = 12)	75%	0.44	2 (16.7)	0.73
Lymph node metastases numbers	0 to 15 (n = 34)	91%	<0.001	0 (0)	0.18
Lymph node metastases numbers	>15 (n = 6)	17%	(HR 0.09, 95% CI 0.02, 0.40)	8 (23.5)	0.18

CI: confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.

ISSN: 1477-7819